269 related articles for article (PubMed ID: 16103233)
1. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
Anand IS; Kuskowski MA; Rector TS; Florea VG; Glazer RD; Hester A; Chiang YT; Aknay N; Maggioni AP; Opasich C; Latini R; Cohn JN
Circulation; 2005 Aug; 112(8):1121-7. PubMed ID: 16103233
[TBL] [Abstract][Full Text] [Related]
2. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein in heart failure: prognostic value and the effect of valsartan.
Anand IS; Latini R; Florea VG; Kuskowski MA; Rector T; Masson S; Signorini S; Mocarelli P; Hester A; Glazer R; Cohn JN;
Circulation; 2005 Sep; 112(10):1428-34. PubMed ID: 16129801
[TBL] [Abstract][Full Text] [Related]
4. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
5. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
Anand IS; Kempf T; Rector TS; Tapken H; Allhoff T; Jantzen F; Kuskowski M; Cohn JN; Drexler H; Wollert KC
Circulation; 2010 Oct; 122(14):1387-95. PubMed ID: 20855664
[TBL] [Abstract][Full Text] [Related]
6. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.
Go AS; Yang J; Ackerson LM; Lepper K; Robbins S; Massie BM; Shlipak MG
Circulation; 2006 Jun; 113(23):2713-23. PubMed ID: 16754803
[TBL] [Abstract][Full Text] [Related]
7. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT.
Krum H; Latini R; Maggioni AP; Anand I; Masson S; Carretta E; Ingrillì F; Pettinati G; Glazer R; Tognoni G; Cohn J
Int J Cardiol; 2007 Jun; 119(1):48-53. PubMed ID: 17049646
[TBL] [Abstract][Full Text] [Related]
8. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
Baruch L; Glazer RD; Aknay N; Vanhaecke J; Heywood JT; Anand I; Krum H; Hester A; Cohn JN
Am Heart J; 2004 Dec; 148(6):951-7. PubMed ID: 15632877
[TBL] [Abstract][Full Text] [Related]
9. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET.
Komajda M; Anker SD; Charlesworth A; Okonko D; Metra M; Di Lenarda A; Remme W; Moullet C; Swedberg K; Cleland JG; Poole-Wilson PA
Eur Heart J; 2006 Jun; 27(12):1440-6. PubMed ID: 16717081
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894.
Beer TM; Tangen CM; Bland LB; Hussain M; Goldman BH; DeLoughery TG; Crawford ED;
Cancer; 2006 Aug; 107(3):489-96. PubMed ID: 16804926
[TBL] [Abstract][Full Text] [Related]
11. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
Staszewsky L; Wong M; Masson S; Barlera S; Carretta E; Maggioni AP; Anand IS; Cohn JN; Tognoni G; Latini R;
J Card Fail; 2007 Dec; 13(10):797-804. PubMed ID: 18068611
[TBL] [Abstract][Full Text] [Related]
12. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
13. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure.
Tang WH; Tong W; Jain A; Francis GS; Harris CM; Young JB
J Am Coll Cardiol; 2008 Feb; 51(5):569-76. PubMed ID: 18237687
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of discharge hemoglobin level in patients hospitalized for acute heart failure].
Sánchez-Torrijos J; Gudín-Uriel M; Nadal-Barangé M; Jacas-Osborn V; Trigo-Bautista A; Giménez-Alcalá M; Payá-Serrano R; Ridocci-Soriano F
Rev Esp Cardiol; 2006 Dec; 59(12):1276-82. PubMed ID: 17194423
[TBL] [Abstract][Full Text] [Related]
15. Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study.
Wu AH; Omland T; Wold Knudsen C; McCord J; Nowak RM; Hollander JE; Duc P; Storrow AB; Abraham WT; Clopton P; Maisel AS; McCullough PA;
Am J Hematol; 2005 Nov; 80(3):174-80. PubMed ID: 16247751
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
17. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN
Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728
[TBL] [Abstract][Full Text] [Related]
18. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT).
Butler J; Anand IS; Kuskowski MA; Rector T; Carson P; Cohn JN;
Congest Heart Fail; 2010; 16(5):191-5. PubMed ID: 20887614
[TBL] [Abstract][Full Text] [Related]
19. Association of longitudinal measures of hemoglobin and outcomes after hospitalization for heart failure.
Peterson PN; Magid DJ; Lyons EE; Clarke CL; Zeng C; Fitzgerald A; Lindenfeld J; Kosiborod M; Brand D; Masoudi FA
Am Heart J; 2010 Jan; 159(1):81-9. PubMed ID: 20102871
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O
J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]